MiMedx Income Quality Over Time

MDXG Stock

USD 9.53 0.06 0.63%

With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.

Check out MiMedx Performance and MiMedx Correlation.

The current Income Quality is estimated to decrease to 0.38.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.1)

Earnings Share

0.57

Revenue Per Share

2.447

Quarterly Revenue Growth

0.029

Return On Assets

0.1838

The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Specify up to 10 symbols:

Apply

Cross Equities Income Quality Analysis

Compare MiMedx Group and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Werewolf Therapeutics Income Quality Over Time

Select Fundamental

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
GLUE	0.7975	0.7975	0.7975	0.7975	0.7975	0.7975	0.7975	0.7975	0.7975	0.7975	0.6425	0.8027	0.8522	0.3236	0.31
HOWL	0.9311	0.9311	0.9311	0.9311	0.9311	0.9311	0.9311	0.9311	0.9311	0.9311	1.2383	0.8578	0.7544	0.8727	1.02
IKNA	0.2841	0.2841	0.2841	0.2841	0.2841	0.2841	0.2841	0.2841	0.2841	(2.8499)	0.8547	1.7661	1.0777	1.1698	1.23
STOK	0.9687	0.9687	0.9687	0.9687	0.9687	0.9687	0.9687	0.9687	0.8756	0.9607	0.8082	0.7798	0.3153	0.7743	0.86
IPSC	0.0661	0.0661	0.0661	0.0661	0.0661	0.0661	0.0661	0.0661	0.0661	0.0661	0.7703	0.9288	(0.1073)	0.6464	0.37
EWTX	0.945	0.945	0.945	0.945	0.945	0.945	0.945	0.945	0.945	0.945	0.8546	0.7826	0.7782	0.918	0.95
CCCC	1.0808	1.0808	1.0808	1.0808	1.0808	1.0808	1.0808	1.0808	1.0808	(1.631)	1.0138	1.0366	0.8265	0.8064	0.42
MLYS	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7189	0.7502	0.9806	1.129	0.71
CGEM	0.9549	0.9549	0.9549	0.9549	0.9549	0.9549	0.9549	0.9549	0.9549	0.965	0.5007	0.6436	(1.16)	0.8767	0.51
CVKD	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.1794	0.4224	0.24
GPCR	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8997	0.8452	0.8987	0.8869	0.7
CNTA	1.151	1.151	1.151	1.151	1.151	1.151	1.151	1.151	1.151	1.151	0.9969	0.3565	0.9276	1.0613	0.99
ERAS	0.862	0.862	0.862	0.862	0.862	0.862	0.862	0.862	0.862	0.862	0.3215	0.6484	0.4253	0.8095	0.67
KROS	(5.2749)	(5.2749)	(5.2749)	(5.2749)	(5.2749)	(5.2749)	(5.2749)	(5.2749)	(5.2749)	1.2969	0.8133	1.0579	0.6693	0.8138	0.85
DAWN	0.2658	0.2658	0.2658	0.2658	0.2658	0.2658	0.2658	0.2658	0.2658	0.2658	0.3077	0.6672	0.7728	0.7773	0.45
INZY	1.3551	1.3551	1.3551	1.3551	1.3551	1.3551	1.3551	1.3551	1.3551	0.9537	0.6376	0.8504	0.8613	0.9931	1.03
ZNTL	1.035	1.035	1.035	1.035	1.035	1.035	1.035	1.035	1.035	0.844	0.7324	0.9278	0.6906	0.7113	0.9
SNDX	0.9317	0.9317	0.9317	0.5148	0.7259	0.1007	0.7905	0.7791	0.9266	0.903	0.9741	1.1687	0.8951	0.7671	0.63
PTGX	0.6993	0.6993	0.6993	0.6993	0.6993	0.9682	0.8062	(0.1048)	1.2832	0.538	1.0958	0.8591	0.8488	0.8896	0.63

MiMedx Group and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Werewolf Therapeutics Income Quality description

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

My Equities

My Current Equities and Potential Positions

View All Next

MiMedx Group

MDXG

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Location	Georgia; U.S.A
Exchange	NASDAQ Exchange

USD 9.53

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:

How To Invest In MiMedx

Details

Is MiMedx Stock a good investment?

Details

What is MiMedx's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out MiMedx Performance and MiMedx Correlation.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

MiMedx technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.

Volatility Indicators

View

Value Movement

View

A focus of MiMedx technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of MiMedx trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

MiMedx Income Quality Over Time

Specify up to 10 symbols:

Cross Equities Income Quality Analysis

MiMedx Group and related stocks such as Monte Rosa Therapeutics, Design Therapeutics, and Werewolf Therapeutics Income Quality description

My Equities

My Current Equities and Potential Positions

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY